This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

26 Mar 2012

Amgen Announces Positive Results from Phase-Ib Study of Cholesterol Drug AMG 145

Amgen has reported positive results from a phase-Ib study of AMG 145 in patients with high cholesterol despite statin use.

Amgen's investigational cholesterol-lowering therapy AMG 145 has produced positive results in a recent phase-Ib study involving statin users with high cholesterol.


Researchers tested the drug in 51 patients, who received subcutaneous doses of AMG 145 at regular intervals.


They found that the PCSK9 inhibitor reduced serum low density lipoprotein cholesterol (LDL-C) by up to 81 per cent, compared with placebo, in patients taking low to moderate doses of statins.


The drug also appears to have a good safety profile, with no deaths or serious adverse events reported at the American College of Cardiology Scientific Session in Chicago.


Related News